Brazil considers new role for pharma, medtech to avoid disruptions

03/20/2013 | Clinica (subscription required)

Brazil's regulatory agency Anvisa has proposed that medtech and pharmaceutical firms be required to take active steps to warn the health care system and identify alternative sources before halting any drug production that could disrupt critically needed medications. Currently, companies are required to give six months' notice before stopping manufacture or withdrawing a product from market. Anvisa has three months to turn the proposal into a draft regulation for formal public comment.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX